THURSDAY, June 6 (HealthDay News) -- An expert advisory panel to
the U.S. Food and Drug Administration voted narrowly Thursday to
recommend changing tough safety restrictions on the diabetes drug
Avandia, which was all but banned nearly two years ago because of
reported links to heart problems.
The panel's decision came after a review of data that suggested
the medication might not be as harmful as once thought.
However, because of initial concerns over cardiovascular safety,
Avandia had been taken off drugstore shelves and its use restricted
to patients who first signed a waiver saying they understood the
possible risks. The drug was also dispensed only through specially
But the new recommendation might change all that. Thirteen
members of the 26-person panel voted to alter the safety
Associated Pressreported, while seven voted to remove the
restrictions altogether. Five panelists voted to keep the
restrictions in place, while one panelist voted to withdraw Avandia
from the marketplace.
The exact nature of any changes to current restrictions are yet
to be decided. The FDA is not obligated to follow its advisory
panels' decisions, but it usually does.
The panelists spent the past two days reconsidering evidence
from an independent review by Duke University researchers of
Avandia's original clinical trial, called RECORD. That review did
uncover some previously unreported cases of heart complications and
deaths, but the Duke team concluded that those cases did not
significantly raise the overall risk of heart disease.
"I'm considerably reassured, in light of the reanalysis, that the magnitude of risk we're talking about here is not very great," Dr. Dale Hammerschmidt, of the University of Minnesota, who voted on Thursday to modify the safety limits, told the AP.
The drug's maker, GlaxoSmithKline, which had funded the Duke
review, said it was satisfied with the panel's decision.
"We appreciate the committee's thorough examination of the RECORD results and will continue to work with the FDA as it considers the recommendation of the committee," the company's chief medical officer, Dr. James Shannon, said in a statement. "We continue to believe that Avandia is a safe and effective treatment option for type 2 diabetes when used for the appropriate patient and in accordance with labeling."
Not everyone is likely to be so pleased. The FDA's
reconsideration of Avandia's safety has prompted stinging criticism
from the drug's detractors, who say the agency is trying to save
face following a very public embarrassment over the drug.
"This is a drug that has essentially been off the market in almost the entire world for the last three years. It has been banned in most countries, and is available in the United States under such strict requirements that only 3,000 patients now take it," said Dr. Steven Nissen, the Cleveland Clinic cardiologist who first led the charge against Avandia. "It's really about the FDA wanting to clean up its image, not about whether the drug is actually safe or unsafe."
But the FDA defended its decision to review the Duke re-analysis
of the original trial.
"Given the public interest in Avandia, the extensive history of the product and the continued uncertainty of risk, the FDA is holding the advisory committee meeting to have a transparent, public discussion of the results of the RECORD readjudication," FDA spokesperson Morgan Liscinsky said.
Avandia quickly became a blockbuster diabetes drug following its
release in 1999, with sales topping $3 billion in 2006.
But in 2007, Nissen published a study showing that Avandia
raised the risk of heart attack by more than 40 percent. The outcry
that followed led to Senate hearings in which the FDA's drug
approval process came under intense scrutiny.
An FDA analysis of more than 50 studies of Avandia found that
the drug was linked to an increased risk of heart problems. One
study tied Avandia use to more than 47,000 cases of heart attack,
stroke or heart failure during a 10-year period, even though the
company-funded RECORD trial had not found an increased risk of
The FDA ended up pulling Avandia from pharmacy shelves in
November of 2011, placing severe restrictions on the drug that
limited its use to extremely ill diabetics. Patients wanting to
take the medication now must enroll in a special program to qualify
for its use.
Critics called this week's meetings a waste of taxpayer dollars,
arguing that so many concerns have been raised about Avandia's
safety that a green light now from the FDA would be
"It's not an issue of any importance to the medical community," Nissen said. "It's all about the FDA. If the FDA is allowed to whitewash the Avandia affair, it makes it less likely the right thing will be done when issues like this come up in the future," he added.
"Unfortunately, the public is caught in the crossfire," he continued. "The last thing we want to do is promote the use of an agent that is not helpful and is almost certainly harmful in the majority of the people who take it."
Nissen and other critics noted that the Duke review was funded
by GlaxoSmithKline and have questioned the independence of the
A panel of FDA officials had vouched for the Duke report,
however, and argue that its findings deserve scrutiny in a public
"The FDA strongly believes that regulatory decisions should be based on strong scientific evidence. If such evidence becomes available to revisit previous regulatory decisions, it is important for the FDA to consider this evidence in a transparent process," Liscinsky said. "The FDA is critically evaluating the RECORD readjudication. Once the advisory committee meeting has been held and review is complete, the FDA will determine if the results of the readjudication in the context of all the pertinent available data affect the agency's assessment of the risk-benefit information for rosiglitazone [Avandia]."
Dr. George King, director of research for the Joslin Diabetes
Center and a professor of medicine at Harvard Medical School, said
Avandia use needs to be restricted but has no problem with the FDA
taking a look at the new evidence.
"A reanalysis is always good," King said. "Why spend all that money to do the study if you're not going to consider the data, right?"
King noted that Avandia and other drugs in its class, called
thiazolidinediones, occupy a unique place in diabetes treatment.
They decrease insulin resistance in the body by binding to
receptors in fat cells and making those cells more responsive to
"We don't have any other diabetic medications that can actually improve insulin resistance," he said. "The others either promote more insulin production from the pancreas, make you urinate out more glucose or help your liver handle glucose better."
On the other hand, thiazolidinediones also cause problems with
fluid retention. "In diabetic patients who are older, almost all of
them have some kind of cardiovascular problem," King noted. "If you
retain fluid, you are going to have increased risk for
cardiovascular problems and mortality."
Both sides in the debate have a point, King concluded.
"From my view of it, it does have a niche for use, but the restrictions have to be there," he said. "The people who think it is absolutely safe are absolutely not right, but others who are focused on finding fault with it are overlooking some benefits."
For more on the latest look at Avandia, go to the
U.S. Food and Drug Administration.
EBSCO Information Services is fully accredited by URAC. URAC is an independent, nonprofit health care accrediting organization dedicated to promoting health care quality through accreditation, certification and commendation.
Please be aware that this information is provided to supplement the care provided by your physician. It is neither intended nor implied to be a substitute for professional medical advice. CALL YOUR HEALTHCARE PROVIDER IMMEDIATELY IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY. Always seek the advice of your physician or other qualified health provider prior to starting any new treatment or with any questions you may have regarding a medical condition.
Copyright © EBSCO Information Services. All rights reserved.